Zacks Research Analysts Lower Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Corcept Therapeutics in a report released on Wednesday, March 19th. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.17 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.63 EPS and Q1 2026 earnings at $0.45 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

A number of other equities analysts also recently commented on the company. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Piper Sandler upped their price objective on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 target price on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $58.32 on Monday. The company has a market cap of $6.15 billion, a PE ratio of 46.29 and a beta of 0.61. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $75.00. The firm has a 50-day simple moving average of $61.79 and a 200 day simple moving average of $54.29. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Insider Activity at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 2,924 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the completion of the sale, the chief executive officer now owns 3,019,411 shares of the company’s stock, valued at $183,912,324.01. This represents a 0.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,627 shares of company stock worth $2,557,674 in the last three months. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of Corcept Therapeutics by 50.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,724 shares of the biotechnology company’s stock worth $389,000 after buying an additional 2,578 shares in the last quarter. Cache Advisors LLC acquired a new position in Corcept Therapeutics during the fourth quarter worth about $378,000. Public Employees Retirement System of Ohio raised its position in Corcept Therapeutics by 269.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 2,086 shares in the last quarter. Vise Technologies Inc. acquired a new stake in Corcept Therapeutics in the 4th quarter valued at about $204,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Corcept Therapeutics by 11.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,713 shares of the biotechnology company’s stock valued at $11,323,000 after purchasing an additional 22,361 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.